Skip to main content
Premium Trial:

Request an Annual Quote

Waters' Q1 Revenues Rise 14 Percent on 'Broad-Based' Growth

NEW YORK (GenomeWeb News) — Waters today said first-quarter revenue increased 14 percent and net income jumped 26 percent.
 
Total revenue for the three months ended March 31 rose to $330.8 million from $290 million year over year.
 
CEO Doug Berthiaume said the “strong start for 2007” represents continued growth from 2006, and said the “broad-based” growth was “indicative of a very positive response to our newly introduced instrument systems and consumable products.”
 
R&D spending dipped to $18.7 million from $19 million in the prior-year period.
 
Net income grew to $55.9 million from $44.2 million year over year.
 
As of March 31, Waters had $503.7 million in cash and cash equivalents.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.